Preclinical Pharmacology of the Taxanes: Implications of the Differences

Preclinical Pharmacology of the Taxanes: Implications of the Differences Joseph Gligorov, Jean Pierre Lotz Oncologist 2004; 9(Suppl 2): 3-8 Author Information and Disclosures Target Audience: Physicians who wish to advance their current knowledge of clinical cancer medicine in clinical pharmacology and are involved in providing patient care in a cancer care environment. Method of Physician Participation: Read course materials, complete course quiz and evaluation form (optional). Learning Objectives After completing this course, the reader should be able to: Identify the differences in molecular pharmacology of the taxanes. Describe the impact of the pharmacokinetic and pharmacodynamic profiles of the taxanes on their administration and toxicity. Outline the toxicity profiles of paclitaxel and docetaxel. The NIH/FAES designates this educational activity for a maximum of 1 AMA PRA Category 1 Credits™. Physicians should only claim credit commensurate with the extent of their participation in the activity.

CME Activity Information Accreditation CME Instructions For Credit Privacy Statement Hardware/Software Requirements Release Date: May 25, 2004 Most Recent Review: May 25, 2004* Most Recent Update: May 25, 2004 Date Credit Expires: Apr. 10, 2007 Time to Complete: 1 hour Medium: Internet Online *Click here to learn more about our review process.

Click Here to return to the complete course listing of Microtubule Stabilization in the Treatment of Solid Tumors: Role of the Taxanes.